(RTTNews) - Cyclo Therapeutics, Inc. (CYTH) on Friday announced promising preliminary data from its ongoing Phase 3 TransportNPC study, evaluating Trappsol Cyclo for the treatment of Niemann-Pick ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback